{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:34:12Z","timestamp":1791995652170,"version":"4.4.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T00:00:00Z","timestamp":1556841600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Clementia Pharmaceuticals Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13023-019-1068-7","type":"journal-article","created":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T16:04:18Z","timestamp":1556899458000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Natural history of fibrodysplasia ossificans progressiva: cross-sectional analysis of annotated baseline phenotypes"],"prefix":"10.1186","volume":"14","author":[{"given":"Robert J.","family":"Pignolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevi\u00e8ve","family":"Baujat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"De Cunto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Di Rocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward C.","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Keen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Al Mukaddam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim-Hanh Le Quan","family":"Sang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna R.","family":"Grogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick S.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,3]]},"reference":[{"issue":"5","key":"1068_CR1","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/ng1783","volume":"38","author":"EM Shore","year":"2006","unstructured":"Shore EM, Xu M, Feldman GJ, Fenstermacher GJ, Cho T-J, Choi IH, et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet. 2006;38(5):525\u20137.","journal-title":"Nat Genet"},{"issue":"5\u20136","key":"1068_CR2","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.cytogfr.2009.10.006","volume":"20","author":"FS Kaplan","year":"2009","unstructured":"Kaplan FS, Pignolo RJ, Shore EM. The FOP metamorphogene encodes a novel type I receptor that dysregulates BMP signaling. Cytokine Growth Factor Rev. 2009;20(5\u20136):399\u2013407.","journal-title":"Cytokine Growth Factor Rev"},{"key":"1068_CR3","unstructured":"Lilijesthrom M, Bogard B. The global known FOP population. In:  FOP Drug Development Forum. Boston, MA; 2016."},{"issue":"1","key":"1068_CR4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13023-017-0674-5","volume":"12","author":"G Baujat","year":"2017","unstructured":"Baujat G, Choquet R, Bou\u00e9e S, Jeanbat V, Ruel A, Michot C, et al. Prevalence of fibrodysplasia ossificans progressiva (FOP) in France: an estimate based on a record linkage of two national databases. Orphanet J Rare Dis. 2017;12(1):123.","journal-title":"Orphanet J Rare Dis."},{"issue":"1","key":"1068_CR5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1136\/jmg.19.1.35","volume":"19","author":"JM Connor","year":"1982","unstructured":"Connor JM, Evans DA. Genetic aspects of fibrodysplasia ossificans progressiva. J Med Genet. 1982;19(1):35\u20139.","journal-title":"J Med Genet"},{"issue":"1","key":"1068_CR6","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1302\/0301-620X.64B1.7068725","volume":"64","author":"JM Connor","year":"1982","unstructured":"Connor JM, Evans DA. Fibrodysplasia ossificans progressiva. The clinical features and natural history of 34 patients. J Bone Joint Surg Br. 1982;64(1):76\u201383.","journal-title":"J Bone Joint Surg Br"},{"key":"1068_CR7","unstructured":"Kaplan F, Al Mukaddam M, Baujat G, Brown M, Cali A, Cho T-J, et al. The medical management of fibrodysplasia ossificans progressiva: current treatment considerations. Proc Int Clin Counc FOP. 2019;1:1\u2013111."},{"issue":"3","key":"1068_CR8","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/jbmr.2728","volume":"31","author":"RJ Pignolo","year":"2016","unstructured":"Pignolo RJ, Bedford-Gay C, Liljesthrom M, Durbin-Johnson B, Shore EM, Rocke DM, et al. The natural history of flare-ups in Fibrodysplasia Ossificans Progressiva (FOP): a comprehensive global assessment. J Bone Miner Res. 2016;31(3):650\u20136.","journal-title":"J Bone Miner Res"},{"issue":"3","key":"1068_CR9","doi-asserted-by":"publisher","first-page":"686","DOI":"10.2106\/JBJS.I.00705","volume":"92","author":"FS Kaplan","year":"2010","unstructured":"Kaplan FS, Zasloff MA, Kitterman JA, Shore EM, Hong CC, Rocke DM. Early mortality and cardiorespiratory failure in patients with fibrodysplasia ossificans progressiva. J Bone Joint Surg Am. 2010;92(3):686\u201391.","journal-title":"J Bone Joint Surg Am"},{"issue":"2","key":"1068_CR10","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2106\/00004623-199302000-00008","volume":"75","author":"RB Cohen","year":"1993","unstructured":"Cohen RB, Hahn GV, Tabas JA, Peeper J, Levitz CL, Sando A, et al. The natural history of heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. A study of forty-four patients. J Bone Joint Surg Am. 1993;75(2):215\u20139.","journal-title":"J Bone Joint Surg Am"},{"issue":"4","key":"1068_CR11","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.bone.2012.07.002","volume":"51","author":"A Morales-Piga","year":"2012","unstructured":"Morales-Piga A, Bachiller-Corral J, Trujillo-Tiebas MJ, Villaverde-Hueso A, Alonso-Ferreira V, Vazquez-Diaz M, et al. Fibrodysplasia ossificans progressiva in Spain: epidemiological, clinical, and genetic aspects. Bone. 2012;51(4):748\u201355.","journal-title":"Bone."},{"issue":"6","key":"1068_CR12","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1093\/qjmed\/89.6.445","volume":"89","author":"R Smith","year":"1996","unstructured":"Smith R, Athanasou NA, Vipond SE. Fibrodysplasia (myositis) ossificans progressiva: clinicopathological features and natural history. QJM Mon J Assoc Physicians. 1996;89(6):445\u20136.","journal-title":"QJM Mon J Assoc Physicians"},{"key":"1068_CR13","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.bone.2017.04.015","volume":"101","author":"FS Kaplan","year":"2017","unstructured":"Kaplan FS, Al Mukaddam M, Pignolo RJ. A cumulative analogue joint involvement scale (CAJIS) for fibrodysplasia ossificans progressiva (FOP). Bone. 2017;101:123\u20138.","journal-title":"Bone."},{"key":"1068_CR14","unstructured":"US Food and Drug Administration. Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. \n                    https:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm193282.pdf\n                    \n                  . Published December 2009. Accessed 20 Sep 2017."},{"issue":"7","key":"1068_CR15","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s11136-009-9496-9","volume":"18","author":"RD Hays","year":"2009","unstructured":"Hays RD, Bjorner JB, Revicki DA, Spritzer KL, Cella D. Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items. Qual Life Res Int J Qual Life Asp Treat Care Rehabil. 2009;18(7):873\u201380.","journal-title":"Qual Life Res Int J Qual Life Asp Treat Care Rehabil"},{"issue":"4","key":"1068_CR16","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s11136-013-0581-8","volume":"23","author":"CB Forrest","year":"2014","unstructured":"Forrest CB, Bevans KB, Pratiwadi R, et al. Development of the PROMIS((R)) pediatric global health (PGH-7) measure. Qual Life Res Int J Qual Life Asp Treat Care Rehabil. 2014;23(4):1221\u201331.","journal-title":"Qual Life Res Int J Qual Life Asp Treat Care Rehabil."},{"issue":"8","key":"1068_CR17","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1517\/21678707.2015.1063415","volume":"3","author":"P Gavin","year":"2015","unstructured":"Gavin P. The importance of natural histories for rare diseases. Expert Opin Orphan Drugs. 2015;3(8):855\u20137.","journal-title":"Expert Opin Orphan Drugs"},{"issue":"2","key":"1068_CR18","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.bone.2013.09.002","volume":"57","author":"W Zhang","year":"2013","unstructured":"Zhang W, Zhang K, Song L, et al. The phenotype and genotype of fibrodysplasia ossificans progressiva in China: a report of 72 cases. Bone. 2013;57(2):386\u201391.","journal-title":"Bone."},{"key":"1068_CR19","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.bone.2017.08.009","volume":"109","author":"FS Kaplan","year":"2018","unstructured":"Kaplan FS, Al Mukaddam M, Pignolo RJ. Acute unilateral hip pain in fibrodysplasia ossificans progressiva (FOP). Bone. 2018;109:115\u20139.","journal-title":"Bone."},{"key":"1068_CR20","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/1750-1172-6-80","volume":"6","author":"RJ Pignolo","year":"2011","unstructured":"Pignolo RJ, Shore EM, Kaplan FS. Fibrodysplasia ossificans progressiva: clinical and genetic aspects. Orphanet J Rare Dis. 2011;6:80.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"1068_CR21","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/humu.20868","volume":"30","author":"FS Kaplan","year":"2009","unstructured":"Kaplan FS, Xu M, Seemann P, Connor JM, Glaser DL, Carroll L, et al. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Hum Mutat. 2009;30(3):379\u201390.","journal-title":"Hum Mutat"}],"updated-by":[{"DOI":"10.1186\/s13023-019-1096-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T00:00:00Z","timestamp":1558569600000}}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-1068-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-019-1068-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-1068-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T23:08:10Z","timestamp":1588374490000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-019-1068-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,3]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1068"],"URL":"https:\/\/doi.org\/10.1186\/s13023-019-1068-7","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s13023-019-1096-3","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,3]]},"assertion":[{"value":"9 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2019","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version of this article [1] unfortunately included an error to an author\u2019s name. Author Maja Di Rocco was erroneously presented as Maja DiRocco.The correct author name has been included in the author list of this Correction article and is already updated in the original article.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved initially by The Committee on Human Research at the University of California San Francisco (approval number: 14\u201313854) and subsequently approved by the ethics committees at the six other study site institutions (University of Pennsylvania Institutional Review Board; Comit\u00e9 de Protection des Personnes, Ile de France II; Comitado Etico Regionale San Martino; Hospital Italiano Comit\u00e9 de \u00c9tica de Protocolos de Investigacion; NHS Health Research Authority, London-Stanmore Research Ethics Committee; Metro South Human Research Ethics Committee). The study was registered at  (NCT02322255), and performed in accordance with the Declaration of Helsinki (2008).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AW, BW, and DRG are Clementia employees. All other authors received funding from Clementia to implement and conduct the study. In addition, the authors\u2019 travel expenses were paid to attend Investigator meetings at which study activities and results were discussed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"98"}}